KRAS and colorectal cancer: Murine models of KRASG12D colorectal cancer have shown that upregulation of signaling in the MAPK pathway with oncogenic KRAS mutations promotes tumor dedifferentiation for which TGFβ signaling may compensate against tumorigenesis (41).